Patient P-01582
Therapy response
Declining
Tolerance
Unstable
GI state
Unstable
Inflammatory state
Unstable
Nutritional resilience
Unstable
Discontinuation risk
83%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 NBL-101 started — Baseline state S14
- Day 45 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 59 GI-04 recommended — GI Support Protocol GI-04
- Day 60 Patient accepted — Started GI-04 in the companion
- Day 65 ME-01 recommended — Monitoring Escalation ME-01
- Day 66 Patient accepted — Started ME-01 in the companion
- Day 68 No meaningful change — GI Support Protocol GI-04
- Day 69 Deterioration detected before clinical escalation — Monitoring Escalation ME-01
What changed?
Trajectory began diverging from predicted response on Day 45.
Primary contributors, last 14 days
- Toxicity+15
- Inflammatory activity+13
- Treatment adherence-7
- GI instability-4
- Nutritional resilience-2
What helped?
- GI Support Protocol GI-04Day 59Result: no meaningful change
- Monitoring Escalation ME-01Day 65Result: deterioration detected before clinical escalation
LIFE OS recommendation
Dietary Support Protocol NP-02
61%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 66% showed improvement
- median effect visible after 10 days
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Mucosal barrier integrity ↓90
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 67 and rising
- WearableSleep 6.1 h, below personal baseline
- Inflammatory signalling ↑85
- DNAIL6 -174 variant raises baseline inflammatory tone
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 71
- WearableHRV 37 ms, trending down
- Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 23/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
- Drug metabolism and exposure ↑60
- DNACYP2D6 poor metabolizer → higher exposure
- BloodToxicity index 60
- Autonomic recovery ↓45
- WearableResting HR 75 bpm
- WearableShort sleep window
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- IL6 -174 G/CHigher inflammatory tone
- CYP2D6 Poor metabolizerHigher exposure at standard dose
Microbiome
Shannon diversity 2.4 · butyrate capacity 23/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisHigh
- Bifidobacterium longumLow
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 38 ms
- Sleep
- 6.1 h
- Steps
- 5,773
- Resting HR
- 74 bpm
Daily log: GI score 67, nutritional resilience 31, adherence 41.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- Keep the current walking rhythm
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.